![]() |
市場調查報告書
商品編碼
2179092
人工智慧驅動的分散式臨床試驗平台市場預測至2034年:全球分析(按組件、平台類型、技術、部署模式、應用和區域分類)AI-Powered Decentralized Clinical Trial Platforms Market Forecasts to 2034 - Global Analysis By Component (Software and Services), Platform Type, Technology, Deployment Mode, Application and By Geography |
||||||
根據 Stratistics MRC 的數據,全球人工智慧驅動的去中心化臨床試驗平台市場預計將在 2026 年達到 26 億美元,在預測期內以 20.3% 的複合年成長率成長,到 2034 年達到 114 億美元。
人工智慧驅動的去中心化臨床試驗平台市場涵蓋了整合人工智慧、遠端患者監護、電子知情同意和臨床數據分析的數位化解決方案,支援在傳統研究機構之外進行臨床試驗。對以患者為中心的研究、快速招募受試者和高效臨床試驗管理的需求不斷成長,正在推動市場發展。機器學習、穿戴式裝置和雲端平台的整合增強了病患參與度、資料收集和試驗監護。對數位化臨床研究投入的增加,為智慧去中心化臨床試驗平台創造了機會。
對以患者為中心的臨床試驗和遠距醫療技術的需求日益成長
對以患者為中心的臨床試驗和遠端研究技術日益成長的需求正在推動市場成長。製藥公司和合約研究組織 (CRO) 正在採用分散式臨床試驗平台,以提高受試者的獲取率、減少現場訪視次數並簡化臨床研究流程。人工智慧技術支援自動化受試者招募、合格篩選、遠端監測和臨床數據分析。對受試者保留率和營運效率的日益重視正在推動數位化臨床試驗的普及。穿戴式感測器、遠端醫療和基於雲端的臨床研究基礎設施的進步進一步增加了對智慧分散式臨床試驗解決方案的需求。
分散式臨床試驗中的資料隱私問題和複雜的監管要求
對資料隱私的擔憂以及分散式臨床試驗複雜的監管要求正在阻礙市場成長。人工智慧驅動的臨床研究平台處理高度敏感的患者訊息,因此需要安全的資料儲存、存取控制以及遵守適用的醫療保健法規。電子知情同意、遠端監測和臨床數據檢驗等方面的區域差異也使部署變得複雜。將數位平台與現有臨床試驗管理系統整合也面臨技術挑戰。高昂的部署成本、受試者數位素養不足以及對數據準確性的擔憂都可能進一步延緩其普及。
擴大人工智慧驅動的患者招募和遠端臨床試驗監測
人工智慧驅動的受試者招募和遠距臨床試驗監查的擴展帶來了巨大的成長機會。製藥公司和研究機構正在投資智慧平台,以識別合格的受試者、提高試驗入組率並支持持續的病人參與。人工智慧驅動的分析可以輔助最佳化試驗方案、進行風險評估並及早發現試驗偏差。穿戴式醫療設備和遠端醫療的日益普及使得分散式資料收整合為可能。生成式人工智慧、預測分析和可互通臨床平台的進步有望加速治療研究計畫的商業化進程。
人工智慧產生的臨床見解中的網路安全漏洞和可靠性挑戰。
人工智慧產生的臨床見解存在網路安全漏洞和可靠性問題,對市場發展構成重大挑戰。依賴安全數位基礎設施和可靠患者資料的去中心化臨床試驗平台因此容易受到網路攻擊、未授權存取和資料外洩。演算法偏差、資料集不完整和自動化評估不準確都會影響臨床研究的品質。監管機構對人工智慧驅動決策的審查可能會使技術應用更加複雜。與現有臨床試驗管理平台的競爭以及遠端服務保險報銷的不確定性可能會進一步限制市場成長。
新冠疫情加速了分散式臨床試驗技術的應用,因為旅行限制、醫療服務中斷以及保持社交距離的必要性限制了傳統的現場研究活動。製藥公司和研究機構擴大採用遠端患者監護、遠距醫療、電子知情同意數位資料收集等方式來維持試驗的連續性。疫情凸顯了靈活的臨床研究基礎設施和以病人為中心的參與模式的重要性。隨後,混合試驗設計的日益普及和對數位化臨床營運的投資推動了市場發展和人工智慧驅動的研究平台的持續應用。
在預測期內,軟體領域預計將佔據最大的市場佔有率。
在對人工智慧驅動的臨床試驗管理、病人參與和臨床數據分析平台的需求不斷成長的推動下,預計軟體領域將在預測期內佔據最大的市場佔有率。製藥公司和研究機構需要整合軟體來管理分散的試驗活動、監測參與者的進展並維護數據品質。雲端研究平台和自動化臨床工作流程的日益普及正在推動軟體投資的成長。預測分析、電子臨床結果評估和智慧數據管理的進步也進一步促進了該領域的成長。
預計在預測期內,生成式人工智慧和大規模語言模型領域將呈現最高的複合年成長率。
在預測期內,生成式人工智慧和大規模語言建模領域預計將呈現最高的成長率,這主要得益於對自動化臨床文件、智慧醫病溝通以及最佳化研究工作流程日益成長的需求。生成式人工智慧技術可以輔助方案製定、合格評估、臨床數據匯總和受試者參與。對人工智慧驅動的藥物研發投入的增加正在推動創新。領域特定語言模型、安全資料處理以及人工監督下的臨床自動化方面的進步有望加速這些技術在分散式研究平台上的應用。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其完善的藥物研發基礎設施、大量的臨床試驗投資以及對數位醫療技術的積極應用。美國正透過製藥公司、合約研究組織 (CRO) 和臨床技術供應商採用分散式試驗解決方案來推動區域發展。對人工智慧、遠端患者監護和雲端研究平台的投資不斷增加,也促進了這些解決方案的應用。醫療機構、生物技術公司和技術開發商之間的合作進一步提升了該地區對智慧臨床試驗平台的需求。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於不斷擴大的藥物研發活動、臨床試驗參與度的提高以及對數位醫療基礎設施投資的持續成長。中國、印度、日本和韓國正在提升其臨床研究能力,並採用技術驅動的試驗管理解決方案。對高效受試者招募和遠端監測日益成長的需求正在推動平台應用。政府主導的醫療數位化以及製藥公司、研究機構和技術提供者之間的夥伴關係預計將加速該地區相關技術的普及。
According to Stratistics MRC, the Global AI-Powered Decentralized Clinical Trial Platforms Market is accounted for $2.6 billion in 2026 and is expected to reach $11.4 billion by 2034 growing at a CAGR of 20.3% during the forecast period. The AI-Powered Decentralized Clinical Trial Platforms Market encompasses digital solutions that integrate artificial intelligence, remote patient monitoring, electronic consent, and clinical data analytics to support clinical trials beyond traditional research sites. Increasing demand for patient-centric research, faster participant recruitment, and efficient clinical trial operations is supporting market development. Integration of machine learning, wearable devices, and cloud-based platforms improves patient engagement, data collection, and trial monitoring. Growing investment in digital clinical research creates opportunities for intelligent decentralized trial platforms.
Increasing demand for patient-centric clinical trials and remote research technologies
Increasing demand for patient-centric clinical trials and remote research technologies is driving market growth. Pharmaceutical companies and contract research organizations are adopting decentralized trial platforms to improve participant accessibility, reduce site visits, and streamline clinical research operations. AI-powered technologies support automated patient recruitment, eligibility screening, remote monitoring, and clinical data analysis. Growing emphasis on patient retention and operational efficiency encourages digital trial adoption. Advancements in wearable sensors, telemedicine, and cloud-based clinical research infrastructure further strengthen demand for intelligent decentralized clinical trial solutions.
Data privacy concerns and complex regulatory requirements for decentralized clinical trials
Data privacy concerns and complex regulatory requirements for decentralized clinical trials restrain market growth. AI-powered clinical research platforms process sensitive patient information, requiring secure data storage, controlled access, and compliance with applicable healthcare regulations. Differences in regional requirements for electronic consent, remote monitoring, and clinical data validation complicate implementation. Integrating digital platforms with existing clinical trial management systems creates technical challenges. High deployment costs, limited digital literacy among participants, and concerns regarding data accuracy may further delay adoption.
Expansion of AI-enabled patient recruitment and remote clinical trial monitoring
Expansion of AI-enabled patient recruitment and remote clinical trial monitoring presents significant growth opportunities. Pharmaceutical sponsors and research organizations are investing in intelligent platforms to identify eligible participants, improve trial enrollment, and support continuous patient engagement. AI-powered analytics can assist with protocol optimization, risk assessment, and early identification of trial deviations. Increasing adoption of wearable medical devices and telemedicine enables decentralized data collection. Advancements in generative AI, predictive analytics, and interoperable clinical platforms are expected to accelerate commercialization across therapeutic research programs.
Cybersecurity vulnerabilities and reliability challenges in AI-generated clinical insights
Cybersecurity vulnerabilities and reliability challenges in AI-generated clinical insights pose significant challenges to market development. Decentralized clinical trial platforms depend on secure digital infrastructure and reliable patient-generated data, creating exposure to cyberattacks, unauthorized access, and information breaches. Algorithmic bias, incomplete datasets, and inaccurate automated assessments may affect clinical research quality. Regulatory scrutiny surrounding AI-assisted decision-making can complicate technology adoption. Competition from established clinical trial management platforms and uncertainty regarding reimbursement for remote services may further restrict market growth.
The COVID-19 pandemic accelerated adoption of decentralized clinical trial technologies as travel restrictions, healthcare disruptions, and social distancing requirements limited conventional site-based research activities. Pharmaceutical companies and research organizations increasingly implemented remote patient monitoring, telemedicine visits, electronic consent, and digital data collection to maintain trial continuity. The pandemic demonstrated the importance of flexible clinical research infrastructure and patient-centric participation models. Growing acceptance of hybrid trial designs and investment in digital clinical operations subsequently supported market development and continued adoption of AI-enabled research platforms.
The software segment is expected to be the largest during the forecast period
The software segment is expected to account for the largest market share during the forecast period due to increasing demand for AI-enabled clinical trial management, patient engagement, and clinical data analytics platforms. Pharmaceutical companies and research organizations require integrated software to manage decentralized trial activities, monitor participant progress, and maintain data quality. Growing adoption of cloud-based research platforms and automated clinical workflows supports software investment. Advancements in predictive analytics, electronic clinical outcome assessments, and intelligent data management further strengthen segment growth.
The generative AI & large language models segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the generative AI & large language models segment is predicted to witness the highest growth rate due to increasing demand for automated clinical documentation, intelligent patient communication, and research workflow optimization. Generative AI technologies can assist with protocol development, eligibility assessment, clinical data summarization, and participant engagement. Growing investment in AI-enabled pharmaceutical research encourages innovation. Advancements in domain-specific language models, secure data processing, and human-supervised clinical automation are expected to accelerate adoption across decentralized research platforms.
During the forecast period, North America is expected to hold the largest market share due to established pharmaceutical research infrastructure, substantial clinical trial investment, and strong adoption of digital healthcare technologies. The United States leads regional development through pharmaceutical sponsors, contract research organizations, and clinical technology providers implementing decentralized trial solutions. Growing investment in artificial intelligence, remote patient monitoring, and cloud-based research platforms supports adoption. Collaboration among healthcare institutions, biotechnology companies, and technology developers further strengthens regional demand for intelligent clinical trial platforms.
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding pharmaceutical research activities, increasing clinical trial participation, and growing investment in digital healthcare infrastructure. China, India, Japan, and South Korea are advancing clinical research capabilities and adopting technology-enabled trial management solutions. Increasing demand for efficient patient recruitment and remote monitoring encourages platform deployment. Government-supported healthcare digitization and partnerships among pharmaceutical companies, research organizations, and technology providers are expected to accelerate regional adoption.
Key players in the market
Some of the key players in the AI-Powered Decentralized Clinical Trial Platforms Market include Medable, Inc., Science 37, THREAD Research, Castor Research Inc., Medidata Solutions, Inc., Veeva Systems Inc., Oracle Corporation, IQVIA Holdings Inc., Signant Health, Clario, ObvioHealth, Curebase, Clinical Ink, Inc., Medrio, Inc., Florence Healthcare, Inc., Viedoc Technologies AB, Jeeva Informatics Solutions Inc., and Saama Technologies, Inc.
In October 2026, Veeva Systems Inc. announced that its Veeva Data Quality System had processed and cleaned clinical data from more than one million participants across over 1,000 studies. The platform automates data reconciliation, improves clinical data quality, and supports faster preparation of analysis-ready trial information.
In September 2026, Medable, Inc. partnered with the MRCT Center to introduce resources supporting investigator oversight in decentralized clinical trials. The initiative addresses responsibilities associated with remote trial activities and supports consistent clinical research oversight.
In September 2026, THREAD Research introduced enhanced digital health data integration capabilities for decentralized and hybrid clinical trials. The platform connects participant information, wearable device data, and operational records to improve trial monitoring, identify emerging risks, and support more efficient clinical research operations.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.